

# Nicole A Doria-Rose

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5139173/nicole-a-doria-rose-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

9,994  
citations

34  
h-index

78  
g-index

78  
ext. papers

13,823  
ext. citations

24.8  
avg, IF

5.59  
L-index

#	Paper	IF	Citations
72	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1920-1931	59.2	1704
71	Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. <i>Science</i> , <b>2010</b> , 329, 856-61	33.3	1327
70	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2427-2438	59.2	737
69	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , <b>2012</b> , 491, 406-12	50.4	624
68	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
67	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , <b>2020</b> , 586, 567-571	50.4	594
66	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , <b>2014</b> , 509, 55-62	50.4	537
65	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 80-82	59.2	392
64	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2259-2261	59.2	298
63	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2037-2050	59.2	276
62	Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. <i>Journal of Virology</i> , <b>2010</b> , 84, 1631-6	6.6	258
61	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , <b>2016</b> , 352, 828-33	33.3	218
60	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , <b>2017</b> , 358, 85-90	33.3	176
59	Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. <i>Science</i> , <b>2013</b> , 340, 751-6	33.3	172
58	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , <b>2018</b> , 24, 857-867	50.5	169
57	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , <b>2015</b> , 21, 1332-6	50.5	154
56	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , <b>2016</b> , 90, 76-91	6.6	151

55	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373, 1372-1377	33.3	150
54	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , <b>2016</b> , 23, 81-90	17.6	126
53	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , <b>2017</b> , 19, 719-732	10.6	123
52	Isolation of human monoclonal antibodies from peripheral blood B cells. <i>Nature Protocols</i> , <b>2013</b> , 8, 1907-1918	15.8	94
51	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373,	33.3	80
50	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	65
49	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , <b>2019</b> , 178, 567-584.e19	56.2	64
48	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	61
47	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , <b>2019</b> , 25, 59-72.e8	23.4	56
46	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	54
45	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , <b>2019</b> , 50, 1513-1529.e9	32.3	53
44	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , <b>2019</b> , 27, 196-206.e6	5.2	48
43	Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. <b>2021</b> ,		46
42	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , <b>2015</b> , 90, 2740-55	6.6	45
41	Rational design of a trisppecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , <b>2018</b> , 9, 877	17.4	43
40	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , <b>2021</b> , 36, 109353	10.6	41
39	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , <b>2019</b> , 50, 677-691.e13	32.3	38
38	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , <b>2018</b> , 22, 1798-1809	10.6	33

37	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , <b>2021</b> , 374, 1343-1353	33.3	32
36	Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	30
35	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , <b>2019</b> , 14, e0215163	3.7	25
34	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. <i>Scientific Reports</i> , <b>2020</b> , 10, 3032	4.9	24
33	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. <i>Cell</i> , <b>2021</b> ,	56.2	24
32	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , <b>2020</b> , 31, 107488	10.6	22
31	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , <b>2021</b> , 371,	33.3	22
30	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.. <i>Cell</i> , <b>2022</b> ,	56.2	22
29	Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants <b>2021</b> ,		21
28	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , <b>2016</b> , 90, 10574-10586	6.6	19
27	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. <i>Immunity</i> , <b>2021</b> , 54, 324-339.e8	32.3	15
26	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	12
25	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		12
24	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	11
23	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007632	7.6	9
22	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3299-3304	15.9	9
21	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	9
20	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , <b>2020</b> , 27, 531-543.e6	23.4	8

19	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates <b>2021</b> ,		8
18	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , <b>2020</b> , 32, 107981	10.6	7
17	Defining the risk of SARS-CoV-2 variants on immune protection.. <i>Nature</i> , <b>2022</b> ,	50.4	7
16	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1530-1534	7	5
15	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway <b>2021</b> ,		4
14	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects <b>2021</b> ,		4
13	Potent anti-viral activity of a trispesific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , <b>2022</b> , 38, 110199	10.6	3
12	Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates		3
11	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225806	3.7	2
10	Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults. <b>2021</b> ,		1
9	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. <i>Cell Reports</i> , <b>2021</b> , 35, 108937	10.6	1
8	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. <b>2022</b> ,		1
7	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , <b>2022</b> , 101477	11.3	0
6	Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice.. <i>STAR Protocols</i> , <b>2022</b> , 3, 101180	1.4	
5	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.. <i>Advanced Science</i> , <b>2022</b> , e2200063	13.6	
4	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
3	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
2	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		

- 1 Toll-like receptor 7-adapter complex modulates interferon- $\beta$  production in HIV-stimulated plasmacytoid dendritic cells **2019**, 14, e0225806